Wockhardt Q4 FY26 Results: Posted FY26 PBT of ₹238 Crore; Q4 Revenue Jumps 30% YoY

Wockhardt reported a major improvement in profitability for FY26. Profit before tax (PBT) stood at ₹238 crore, compared with a loss of ₹16 crore in the previous year. For the March quarter (Q4 FY26), PBT reached ₹189 crore, a sharp recovery from a loss of ₹22 crore in Q4 FY25. Profit after tax for FY26 came in at ₹199 crore versus a loss of ₹57 crore last year, showing a clear turnaround in overall financial performance.

Wockhardt Q4 FY26 Performance Shows Strong Growth

During the March quarter, the company delivered solid growth across key metrics. Revenue rose 30% year-on-year to ₹965 crore, up from ₹743 crore last year. EBITDA grew 147% to ₹196 crore from ₹79 crore, while EBITDA margins improved significantly to 20.3% from 10.7%. This strong quarterly performance helped boost overall annual results.

FY26 Full-Year Financial Performance

For the full financial year, revenue increased 11% to ₹3,373 crore compared to ₹3,033 crore in FY25. EBITDA rose 51% to ₹630 crore from ₹418 crore, and EBITDA margins improved to 18.7% from 13.8%. The company also invested ₹120 crore in research and development during the year, highlighting its continued focus on innovation and future growth.

Impact Of Exceptional Items And Settlements

The company recorded some one-time items during the year, including restructuring and regulatory costs related to its US business and the new labour code. It also settled a bankruptcy estate case and received ₹35.35 crore from a settlement with Dr. Reddy’s, which supported the overall financial improvement.

Biotech Business Drives Growth Momentum

Wockhardt’s biotech operations performed strongly. Quarterly biotech revenue reached ₹252 crore, growing 126% year-on-year, while full-year biotech revenue rose 27% to ₹697 crore. Growth was driven by strong demand in emerging markets and new business partnerships. The company also highlighted upcoming insulin analog launches as a major future opportunity in diabetes care.

Regional Business Performance Remains Robust

The India branded business grew 18% in Q4 and 15% for the full year. The UK market recorded 20% quarterly growth and 13% annual growth. Emerging markets delivered exceptional growth, rising 124% in Q4 and 35% for the full year, supported by strong biotech insulin demand and growth in Latin America. The Irish region also saw steady growth of 12% in Q4 and 16% for FY26.

Wockhardt Share Price Movement

Wockhardt share price (NSE: WOCKPHARMA )closed at ₹1,431.00 on May 4, 2026, gaining ₹35.40 (2.54%) for the day. The stock opened at ₹1,400.00, touched an intraday high of ₹1,439.70 and a low of ₹1,400.00. The company has a market capitalisation of ₹23.24K crore and trades at a P/E ratio of 1,081.54. Over the past year, the stock has recorded a 52-week high of ₹1,868.80 and a 52-week low of ₹1,086.70, and currently does not pay a dividend.

Read More: Adani and GMR Groups Lead as India Inc Promoters Pump $4 Billion into Own Stocks Amid Market Correction!

Conclusion

Wockhardt delivered a strong financial turnaround in FY26, moving back into profitability with solid revenue growth and significant EBITDA improvement. Strong biotech momentum, expanding global markets, and upcoming product launches position the company for continued growth in the coming years.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.